Elasomeran
drugOn this page
Also known as Cx-024414M-1273Moderna covid-19 vaccine rnaMrna-1273Spikevax mrnaTak-919
Summary
Elasomeran (CHEMBL4650491) is an approved oligonucleotide; indicated across 6 conditions including severe acute respiratory syndrome and pneumococcal infection.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Oligonucleotide
- Indications: 6 conditions
- Clinical trials: 42
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL4650491 |
| Name | Elasomeran |
| Type | Oligonucleotide |
| Max phase | 4 |
Also known as: Cx-024414, CX-024414, Elasomeran, M-1273, Moderna covid-19 vaccine rna, Mrna-1273, MRNA-1273, Spikevax mrna, Tak-919, TAK-919, ELASOMERAN
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
6 indications (3 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| severe acute respiratory syndrome | 4 | MONDO:0005091 | MONDO:0100096 |
| pneumococcal infection | 3 | MONDO:0005114 | EFO:0000772 |
| herpes zoster | 3 | MONDO:0005609 | EFO:0006510 |
| respiratory syncytial virus infectious disease | 3 | MONDO:0001577 | EFO:1001413 |
2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 42.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE2 | 11 |
| PHASE3 | 7 |
| Not specified | 6 |
| PHASE4 | 5 |
| PHASE2/PHASE3 | 5 |
| PHASE1/PHASE2 | 4 |
| PHASE1 | 4 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT07266558 | PHASE4 | ACTIVE_NOT_RECRUITING | A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19) |
| NCT04792567 | PHASE4 | COMPLETED | Exploring the Immune Response to SARS-CoV-2 modRNA Vaccines in Patients With Secondary Progressive Multiple Sclerosis (AMA-VACC) |
| NCT04885907 | PHASE4 | COMPLETED | Third Dose of Moderna COVID-19 Vaccine in Transplant Recipients |
| NCT05030974 | PHASE4 | COMPLETED | RECOVAC Repeated Vaccination Study |
| NCT06189040 | PHASE4 | COMPLETED | Immunogenicity After COVID-19 Vaccines in Adapted Schedules |
| NCT04470427 | PHASE3 | COMPLETED | A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19 |
| NCT04649151 | PHASE2/PHASE3 | COMPLETED | A Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 Vaccine in Adolescents 12 to <18 Years Old to Prevent COVID-19 |
| NCT04796896 | PHASE2/PHASE3 | COMPLETED | A Study to Evaluate Safety and Effectiveness of mRNA-1273 COVID-19 Vaccine in Healthy Children Between 6 Months of Age and Less Than 12 Years of Age |
| NCT04805125 | PHASE3 | COMPLETED | Immunocompromised Swiss Cohorts Based Trial Platform |
| NCT04860297 | PHASE3 | COMPLETED | A Study to Evaluate Safety and Immunogenicity of mRNA-1273 Vaccine to Prevent COVID-19 in Adult Organ Transplant Recipients and in Healthy Adult Participants |
| NCT04927065 | PHASE2/PHASE3 | COMPLETED | A Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 (COVID-19) Variants |
| NCT05047770 | PHASE3 | COMPLETED | A Study on the Immune Response and Safety of the Shingles Vaccine and the Influenza Vaccine When Either is Given to Healthy Adults at the Same Time or Following a COVID-19 Booster Vaccine |
| NCT05119855 | PHASE3 | COMPLETED | Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribonucleic Acid (mRNA)-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (COVID-19) Vaccine (V503-076) |
| NCT05158140 | PHASE3 | COMPLETED | Safety, Tolerability, and Immunogenicity of V110 or V114 Co-administered With a Booster Dose of mRNA-1273 in Healthy Adults (V110-911) |
| NCT05168813 | PHASE2/PHASE3 | COMPLETED | Efficacy Study of COVID-19 mRNA Vaccine in Regions With SARS-CoV-2 Variants of Concern |
| NCT05249829 | PHASE2/PHASE3 | COMPLETED | A Study to Evaluate the Immunogenicity and Safety of Omicron Variant Vaccines in Comparison With mRNA-1273 Booster Vaccine for COVID-19 |
| NCT05543356 | PHASE3 | WITHDRAWN | COVID-19 Fourth Dose Study in Australia |
| NCT04894435 | PHASE2 | ACTIVE_NOT_RECRUITING | Mix and Match of the COVID-19 Vaccine for Safety and Immunogenicity |
| NCT04405076 | PHASE2 | COMPLETED | Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 COVID-19 Vaccine in Adults Aged 18 Years and Older |
| NCT04677660 | PHASE1/PHASE2 | COMPLETED | A Study of TAK-919 in Healthy Japanese Adults (COVID-19) |
| NCT04748471 | PHASE2 | UNKNOWN | Immunogenecity and Safety of VaccinemRNA-1273 in Elderly Volunteers (Over 65 y) Compared to Younger Ones (18-45y) |
| NCT04889209 | PHASE1/PHASE2 | COMPLETED | Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) After Receipt of EUA Vaccines |
| NCT04930770 | PHASE2 | WITHDRAWN | Study About the Response to the Administration of a Third Dose of mRNA-1273 Vaccine (COVID-19 Vaccine Moderna) in Renal Transplants With Immunological Failure Initial to Vaccination |
| NCT05000216 | PHASE2 | TERMINATED | COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders |
| NCT05132855 | PHASE1/PHASE2 | UNKNOWN | The Immune Response of Heterologous Boost Third Dose of mRNA and Protein COVID-19 Vaccine |
| NCT05137236 | PHASE2 | COMPLETED | A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Vaccine Boosters |
| NCT05289037 | PHASE2 | COMPLETED | COVID-19 Variant Immunologic Landscape Trial (COVAIL Trial) |
| NCT05315362 | PHASE2 | UNKNOWN | Establishing Immunogenicity and Safety of Needle-free Intradermal Delivery of mRNA COVID-19 Vaccine |
| NCT05324319 | PHASE2 | UNKNOWN | Homologous vs Heterologous Third Vaccination in Kidney Transplant Recipients Kidney Transplant Recipients |
| NCT05345873 | PHASE2 | UNKNOWN | A Study to Evaluate the Immunogenicity and Safety of a Recombinant Protein COVID-19 Vaccine as a Booster Dose in Population Aged 12-17 Years |
| NCT05375838 | PHASE1/PHASE2 | COMPLETED | A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1073 (COVID-19/Influenza) Vaccine in Adults 18 to 75 Years Old |
| NCT05383560 | PHASE2 | COMPLETED | Safety and Immunogenicity of Omicron Variant-Matched Vaccine Booster in Adults |
| NCT04283461 | PHASE1 | COMPLETED | Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2 Infection (COVID-19) |
| NCT04785144 | PHASE1 | COMPLETED | Safety and Immunogenicity Study of a SARS-CoV-2 (COVID-19) Variant Vaccine (mRNA-1273.351) in Naïve and Previously Vaccinated Adults |
| NCT04813796 | PHASE1 | COMPLETED | A Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 Vaccines in Healthy Adults Between 18 Years and 55 Years of Age to Prevent COVID-19 |
| NCT05397223 | PHASE1 | COMPLETED | A Study of Modified mRNA Vaccines in Healthy Adults |
| NCT04715438 | Not specified | ACTIVE_NOT_RECRUITING | Vaccination Against COVID-19 in Cancer |
| NCT04834869 | Not specified | RECRUITING | COVID-19 Vaccines Safety Tracking (CoVaST) |
| NCT04826770 | Not specified | UNKNOWN | Adaptive Immune Response to COVID-19 Vaccination |
| NCT05054218 | Not specified | COMPLETED | COVID-19 Immunogenicity of a Third Dose of mRNA-1273 Vaccine Among Cancer Patients |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).